BioSpecifics Technologies Corp. (NASDAQ: BSTC) is a profitable, commercial-stage biopharmaceutical company that has developed injectable collagenase for 12 clinical indications to date. Injectable collagenase is approved for marketing as XIAFLEX (collagenase clostridium histolyticum or CCH) in the U.S. and abroad for the treatment of adult Dupuytren’s contracture patients with up to two palpable cords in the same palm, and for Peyronie’s disease in men with a palpable plaque and a curvature of 30 degrees or greater at the start of therapy. For more information, visit the company’s website at www.biospecifics.com.